Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
European Journal of Obstetrics, Gynecology, and Reproductive Biology|November 5, 2021
The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinomaYu-Che Ou, Hung-Chun Fu, Jui Lan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2025
Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO studySvetlana Khokhlova, Manwar Abdulelah Alnaqqash, Waleed Bahaj, et al.
American Journal of Cancer Research|June 16, 2025
Prognostic nomogram for advanced epithelial ovarian cancer in the era of homologous recombination testing and PARP inhibitor therapyHao Lin, Yu-Che Ou, Hung-Chun Fu, et al.
Cancer Management and Research|July 15, 2021
Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian CancerHao Lin, Wen-Hsin Chen, Chen-Hsuan Wu, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|August 4, 2021
Comprehensive Clinicopathologic Analysis for Mismatch Repair Protein Expression in Unselected Endometrial Carcinoma Patients With an Emphasis on the Role of MLH1 DeficiencySzu-Wei Huang, Hao Lin, Chao-Cheng Huang, et al.
American Journal of Cancer Research|September 15, 2025
Enhanced prognostic stratification in early-stage epithelial ovarian cancer: multi-histological analysis of neutrophil-to-lymphocyte ratio with particular emphasis on clear cell histologyEn-Ling Sung, Hao Lin, Yu-Che Ou, et al.
Taiwanese Journal of Obstetrics & Gynecology|June 26, 2026
Evaluating homologous recombination status and the efficacy/safety of PARP inhibitors in advanced epithelial ovarianl cancer: A single-institute preliminary experienceChen-Hsuan Wu, Yu-Che Ou, Hung-Chun Fu, et al.
American Journal of Cancer Research|April 20, 2026
Precision chemotherapy duration in advanced ovarian cancer: neoadjuvant cycle optimization and differential treatment adaptation by cytoreduction outcomeWan-Ting Lin, Chen-Hsuan Wu, Hao Lin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 15, 2012
Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinomaAyse Ayhan, Tsui-Lien Mao, Tamer Seckin, et al.
World Journal of Surgical Oncology|April 30, 2026
Optimized sentinel nodes detection in endometrial cancer: intraoperative indocyanine green mapping with postoperative bread-loaf slicing ultrastagingYu-Sheng Huang, Hao Lin, Yu-Che Ou, et al.
Pageof 7